AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

662.355

-8.382-1.25%

Number of Gainers:12

Number of Losers:10

Number of Flat:21

PE:- -

High:674.135

Open:670.735

Low:661.038

Close:670.737

Volume:39.88M

Turnover:164.88M

Market Cap:93.26B

Float Cap:89.88B

Loading ...

Mesoblast Limited - There Can be no Assurance That We Will Ever Achieve or Maintain Profitability

THOMSON REUTERS

Mesoblast Limited - Anticipate That We May Continue to Incur Significant Losses for Foreseeable Future

THOMSON REUTERS

Mesoblast Ltd FY Revenue USD 120.3 Million

THOMSON REUTERS

Mesoblast Ltd FY Loss Attributable USD 57.5 Million

THOMSON REUTERS

ASX Growth Companies With High Insider Ownership Expecting 88% Earnings Growth

Simply Wall St.

3 ASX Growth Stocks With Strong Balance Sheets Investors May Want to Watch

Simply Wall St.

Botanix Pharmaceuticals Ltd - no Dividend was Declared or Paid During Year

THOMSON REUTERS

Botanix Pharmaceuticals Ltd - FY Net Loss Attributable A$69.8 Mln

THOMSON REUTERS

Invion Ltd - FY Prelim Revenues from Ordinary Activities A$384,707

THOMSON REUTERS

Invion Ltd - no Dividends Recommended or Declared During Current Financial Period

THOMSON REUTERS

Neuren Pharmaceuticals H1 Earnings Down; Royalty Income Up

MT Newswires Live

Starpharma FY Revenue AUD 12 Million

THOMSON REUTERS

Neuren Pharmaceuticals H1 Revenue AUD 42.7 Million

THOMSON REUTERS

Starpharma Holdings Ltd-Preliminary Final Report

THOMSON REUTERS

PolyNovo Fiscal 2026 Earnings Down, Revenue Up

MT Newswires Live

Prescient Therapeutics Ltd-Share Purchase Plan Cleansing Notice

THOMSON REUTERS

Polynovo FY Revenues from Ordinary Activities A$150 Million

THOMSON REUTERS

3 ASX Growth Companies With Up To 32% Insider Ownership

Simply Wall St.

3 Founder Led Australian Stocks Retail Investors Are Tracking Right Now

Simply Wall St.

Australia's Prescient Therapeutics Hits Near 2-Month Low on Discounted Raise

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/BK7508/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":662.35516,"timestamp":1787896799803,"preClose":670.73676,"halted":0,"volume":39882195,"delay":0,"changeRate":-0.012496,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-8.381592,"latestTime":"08-28 16:00:00 AEST","open":670.7353,"high":674.135,"low":661.038,"amount":164882904,"amplitude":0.019526,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788134400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787875200000,1787896800000]],"turnoverRate":0.001564,"increases":15,"decrements":12,"flats":16,"marketCap":93261150388.5,"floatMarketCap":89875216921.375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":674.135,"amplitude":0.019526,"preClose":670.73676,"low":661.038,"latestPrice":662.35516,"volume":39882195,"delay":0,"open":670.7353,"prevYearClose":644.3692,"prevWeekClose":662.355,"prevMonthClose":488.077,"prevQuarterClose":464.145,"fiveDayClose":653.313,"twentyDayClose":488.077,"sixtyDayClose":391.1,"secType":"PLATE","market":"AU","turnoverRate":0.001564,"marketCap":93261150388.5,"floatMarketCap":89875216921.375,"timestamp":1787896799803,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":12,"down":10,"flat":21},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662740244","title":"Mesoblast Limited - There Can be no Assurance That We Will Ever Achieve or Maintain Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2662740244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662740244?lang=en_us&edition=fundamental","pubTime":"2026-08-27 06:25","pubTimestamp":1787783102,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0OW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","MSB.AU","BK4139","MESO","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662740240","title":"Mesoblast Limited - Anticipate That We May Continue to Incur Significant Losses for Foreseeable Future","url":"https://stock-news.laohu8.com/highlight/detail?id=2662740240","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662740240?lang=en_us&edition=fundamental","pubTime":"2026-08-27 06:25","pubTimestamp":1787783102,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0OW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","MSB.AU","BK4139","MESO","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662974029","title":"Mesoblast Ltd FY Revenue USD 120.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662974029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662974029?lang=en_us&edition=fundamental","pubTime":"2026-08-27 06:24","pubTimestamp":1787783049,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nPLXMK5SC6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","MSB.AU","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662740291","title":"Mesoblast Ltd FY Loss Attributable USD 57.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662740291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662740291?lang=en_us&edition=fundamental","pubTime":"2026-08-27 06:24","pubTimestamp":1787783049,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nPLXMK5SC6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","MSB.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662742635","title":"ASX Growth Companies With High Insider Ownership Expecting 88% Earnings Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2662742635","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662742635?lang=en_us&edition=fundamental","pubTime":"2026-08-27 03:08","pubTimestamp":1787771298,"startTime":"0","endTime":"0","summary":"The Australian market is experiencing a positive trend, buoyed by falling oil prices and strong performances on Wall Street, with the S&P/ASX 200 recently crossing above its 20-day moving average. In this favorable environment, growth companies with high insider ownership can be particularly appealing to investors seeking potential earnings expansion, as they often demonstrate alignment between management and shareholder interests.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551736-choice1-main-header/1585186738088","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551736-choice1-main-header/1585186738088"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/diversified-financials/asx-hmc/hmc-capital-shares/news/asx-growth-companies-with-high-insider-ownership-expecting-8","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/diversified-financials/asx-hmc/hmc-capital-shares/news/asx-growth-companies-with-high-insider-ownership-expecting-8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SKS.AU","AR1.AU","BK7016","AV1.AU","BK7096","IPX.AU","BK7049","BK7116","TTT.AU","BK7107","BK7110","FRS.AU","BK7062","BK7104","BK7162","BK7508","AWJ.AU","WZR.AU","BK7095","BK7005","BK7036","AEM.AU","TPW.AU","BK7017","BK7093","BK7501","SPL.AU","PDI.AU","BK7023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662262744","title":"3 ASX Growth Stocks With Strong Balance Sheets Investors May Want to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2662262744","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662262744?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:33","pubTimestamp":1787762029,"startTime":"0","endTime":"0","summary":"Central banks are still weighing further tightening as inflation proves stubborn, which keeps pressure on many companies. That backdrop makes earnings growth even more valuable. The Healthy high growth potential screener focuses on stocks where analysts expect strong earnings growth and balance sheets that can better handle higher rates. This article highlights three of the most compelling stocks from that screener to help you focus your research.\nThe stocks below are only a small sample,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/3-asx-growth-stocks-with-strong-balance-sheets-investors-may","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/3-asx-growth-stocks-with-strong-balance-sheets-investors-may","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PMDE","BK4211","VGFPF","LYC.AU","RGLO","MVPS","BK7095","BK7104","BK7501","FEBU","BK7506","BK7067","ISBC","JOYT","BK7508","MSB.AU","WGX.AU","VOTE","GXDW","BK7507","DECU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662879531","title":"Botanix Pharmaceuticals Ltd - no Dividend was Declared or Paid During Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2662879531","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662879531?lang=en_us&edition=fundamental","pubTime":"2026-08-26 15:54","pubTimestamp":1787730880,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0GV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7502","BOT.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662795315","title":"Botanix Pharmaceuticals Ltd - FY Net Loss Attributable A$69.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795315","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662795315?lang=en_us&edition=fundamental","pubTime":"2026-08-26 15:54","pubTimestamp":1787730880,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0GV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7502","BK7508","BOT.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662953167","title":"Invion Ltd - FY Prelim Revenues from Ordinary Activities A$384,707","url":"https://stock-news.laohu8.com/highlight/detail?id=2662953167","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662953167?lang=en_us&edition=fundamental","pubTime":"2026-08-26 15:54","pubTimestamp":1787730865,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0E3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","BK7509","IVX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662311795","title":"Invion Ltd - no Dividends Recommended or Declared During Current Financial Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2662311795","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662311795?lang=en_us&edition=fundamental","pubTime":"2026-08-26 15:54","pubTimestamp":1787730865,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0E3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7509","IVX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662763421","title":"Neuren Pharmaceuticals H1 Earnings Down; Royalty Income Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2662763421","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662763421?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:28","pubTimestamp":1787704117,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  logged AU$0.0381 in EPS for the first half of the year, compared with AU$0.1165 a year ago, a Wednesday filing showed.For the six months ended June 30, royalty income was AU$33.2 million versus AU$28.3 million previously, the Australia-listed pharmaceutical company added.The board declared an interim dividend of AU$0.15 per share, payable Oct. 7 to shareholders on record as of Sept. 16.The company expects royalties of $53 million to $56 million for the full year 2026 after partner Acadia lifted guidance for global DAYBUE net sales to $480 million to $510 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK7508","NEU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662056768","title":"Starpharma FY Revenue AUD 12 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662056768","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662056768?lang=en_us&edition=fundamental","pubTime":"2026-08-26 07:46","pubTimestamp":1787701578,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nPLXTR2ZQF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPL.AU","BK7096","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662684667","title":"Neuren Pharmaceuticals H1 Revenue AUD 42.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662684667","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662684667?lang=en_us&edition=fundamental","pubTime":"2026-08-26 07:27","pubTimestamp":1787700422,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nPLXQDJSS5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NEU.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662768110","title":"Starpharma Holdings Ltd-Preliminary Final Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2662768110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662768110?lang=en_us&edition=fundamental","pubTime":"2026-08-26 07:24","pubTimestamp":1787700243,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUEGVMLZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","SPL.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662080750","title":"PolyNovo Fiscal 2026 Earnings Down, Revenue Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2662080750","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662080750?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:46","pubTimestamp":1787698001,"startTime":"0","endTime":"0","summary":"PolyNovo (ASX:PNV) logged AU$0.0105 in earnings per share for fiscal 2026, compared with AU$0.0189 a year ago, a Wednesday filing showed.For the 12 months ended June 30, total revenue was AU$150 million versus AU$129.2 million previously, the Australia-listed medical technology company added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PNV.AU","BK7508","BK7126"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662750700","title":"Prescient Therapeutics Ltd-Share Purchase Plan Cleansing Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2662750700","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662750700?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:46","pubTimestamp":1787697960,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUEWR71Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","PTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662757459","title":"Polynovo FY Revenues from Ordinary Activities A$150 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662757459","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662757459?lang=en_us&edition=fundamental","pubTime":"2026-08-26 05:56","pubTimestamp":1787694988,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nPLXWSNSJ5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PNV.AU","BK7126","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662575087","title":"3 ASX Growth Companies With Up To 32% Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2662575087","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662575087?lang=en_us&edition=fundamental","pubTime":"2026-08-26 03:08","pubTimestamp":1787684893,"startTime":"0","endTime":"0","summary":"As the Australian Securities Exchange (ASX) prepares for a strong start, buoyed by positive corporate reporting and declining oil prices, investors are keenly observing market dynamics amid global trade tensions and energy sector shifts. In this environment, growth companies with substantial insider ownership can offer intriguing opportunities as they often signal confidence in the company's potential amidst evolving economic landscapes.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-frs/forrestania-resources-shares/news/3-asx-growth-companies-with-up-to-32-insider-ownership","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-frs/forrestania-resources-shares/news/3-asx-growth-companies-with-up-to-32-insider-ownership","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QFN.AU","ZYAU.AU","GIVE.AU","IISV.AU","BK7096","AEM.AU","BK7023","STW.AU","OZR.AU","SKS.AU","XKO.AU","FRS.AU","WZR.AU","IOZ.AU","BBOZ.AU","BK7508","BK7110","BK4141","BK7062","XJO.AU","VAP.AU","SLF.AU","BK7036","IMLC.AU","MFG.AU","BK4526","BK7095","BK7104","XAO.AU","IIGF.AU","BK4543","QRE.AU","DACE.AU","PDI.AU","AWJ.AU","TTT.AU","GEAR.AU","E200.AU","ASX","AR1.AU","AV1.AU","OZF.AU","BK7094","SPL.AU","AYA.AU","EIGA.AU","VAS.AU","ASX.AU","BK7039","BEAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662375941","title":"3 Founder Led Australian Stocks Retail Investors Are Tracking Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2662375941","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662375941?lang=en_us&edition=fundamental","pubTime":"2026-08-25 23:25","pubTimestamp":1787671538,"startTime":"0","endTime":"0","summary":"When central banks keep liquidity flowing, like the PBoC is doing through reverse repos and a sizable MLF, it highlights how dependent markets are on confidence and clear decision makers. Founder led companies tap into that same idea. You get leaders with skin in the game who are often wired for long term resilience. This article highlights three founder led stocks from our screener that fit that mindset today.\nThe stocks in this article are just a sample, and the full founder led screen...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/3-founder-led-australian-stocks-retail-investors-are-trackin-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/3-founder-led-australian-stocks-retail-investors-are-trackin-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["STW.AU","FLT.AU","BK7042","ZYAU.AU","BK7043","BEAR.AU","BK7067","OZR.AU","DACE.AU","EIGA.AU","IIGF.AU","BK7070","GEAR.AU","IISV.AU","VAP.AU","BK7046","GIVE.AU","ISBC","BK7511","QFN.AU","BBOZ.AU","VAS.AU","QRE.AU","MAQ.AU","XAO.AU","XKO.AU","BK4211","MQG.AU","XJO.AU","IOZ.AU","IMLC.AU","E200.AU","BK7501","MSB.AU","BK7508","SLF.AU","OZF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662478598","title":"Australia's Prescient Therapeutics Hits Near 2-Month Low on Discounted Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2662478598","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662478598?lang=en_us&edition=fundamental","pubTime":"2026-08-25 12:57","pubTimestamp":1787633876,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Prescient Therapeutics hits near 2-month low on discounted raise** Shares of Australia's Prescient TherapeuticsPTX.AXfall as much as 4.2%, their lowest level since July 2** Shares hit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL6N44M092:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PTX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":130,"code":"91000000","status":"200"}]}}